1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

5 trials 1 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

2 Completed trials

2 Sponsors

15 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase I (FiH): 1

Oversight events:

28 temporary halts across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 4 Colorectal cancer 2

Sponsors using this IMP

Novartis Pharma AG 4 University Hospital Maastricht 1

All trials

5 total

Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation Recruiting

2023-506716-41-00 Phase I/II 5 countries Novartis Pharma AG
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Phase I (FiH) 7 countries Novartis Pharma AG
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Phase II 10 countries Novartis Pharma AG
Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted

2023-510082-10-00 Phase III 9 countries Novartis Pharma AG
STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases Ended

2023-505721-13-00 Phase II 1 country University Hospital Maastricht

Showing 1–5 of 5 trials

← All drugs A–Z